A novel multi-objective genetic algorithm improves task completion rates by 28.6 percent while reducing costs for ...
A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707). This is an ASCO ...